Cannabis Science Inc  

(Public, OTCMKTS:CBIS)   Watch this stock  
Find more results for PINK:CBIS
+0.0001 (0.69%)
After Hours: 0.0144 0.0000 (0.00%)
Aug 26, 4:02PM EDT  
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.01 - 0.01
52 week 0.01 - 0.04
Open 0.01
Vol / Avg. 3.29M/8.51M
Mkt cap 28.52M
P/E     -
Div/yield     -
EPS -0.01
Shares 1.97B
Beta 2.45
Inst. own 0%

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -113686.70% -43267.46%
Operating margin -116040.30% -42999.41%
EBITD margin - -30281.62%
Return on average assets -687.85% -1202.52%
Return on average equity - -
Employees 5 -
CDP Score - -


Suite B #254, 6946 North Academy Blvd
United States - Map
+1-888-8890888 (Phone)

Website links


Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company's subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Officers and directors

Raymond C Dabney Chief Executive Officer, Director
Age: 50
Robert Kane Chief Financial Officer, Director
Age: 39
Chad Steven Johnson Esq. Chief Operating Officer, General Legal Counsel, Director
Age: 46
Richard Ogden Chief Scientific Officer
Age: 60
Allen A. Herman Chief Medical Officer
Mario Lap Director
Age: 63